New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
07:14 EDTCELG, XLRNAcceleron, Celgene on track to initiate sotatercept or ACE-536 study
Acceleron Pharma (XLRN) provided an update on the status of its research and development programs at the Piper Jaffray 25th Annual Healthcare Conference. New interim clinical data from the phase 2 trial of sotatercept in patients with beta-thalassemia will be presented. The presentation will include new interim data from the 0.5 mg/kg dose group as well as data from the 0.1 and 0.3 mg/kg dose groups in this trial. Sotatercept and ACE-536 clinical trials in beta-thalassemia and myelodysplastic syndromes are progressing on schedule. Celgene (CELG) and its collaborators continue to explore sotatercept in additional clinical studies including anemia of chronic kidney disease, Diamond-Blackfan anemia, myelofibrosis and multiple myeloma. Additionally, Acceleron and Celgene are exploring the preclinical activity of sotatercept and ACE-536 in other red blood cell disorders including Sickle Cell Disease. Acceleron and Celgene remain on track to initiate a registration enabling study with either sotatercept or ACE-536 by the end of 2014 or the beginning of 2015.
News For XLRN;CELG From The Last 14 Days
Check below for free stories on XLRN;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
16:44 EDTXLRN, CELGAcceleron, Celgene announce interim clinical data for sotatercept
Subscribe for More Information
15:35 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
07:41 EDTCELGAlliqua to launch Biovance human amniotic membrane allograft product
Alliqua (ALQA) will launch its Biovance human amniotic membrane allograft product. Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics, a subsidiary of Celgene (CELG), to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types. With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.
April 22, 2014
07:40 EDTCELGCelgene weakness has created attractive entry point, says Stifel
Subscribe for More Information
07:23 EDTXLRNNational Kidney Foundation to hold a meeting
Subscribe for More Information
April 16, 2014
08:34 EDTCELG, XLRNPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
April 10, 2014
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use